NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma

被引：0

作者：

Vilde Drageset Haakensen

Anna K. Nowak

Espen Basmo Ellingsen

Saima Jamil Farooqi

Maria Moksnes Bjaanæs

Henrik Horndalsveen

Tine Mcculloch

Oscar Grundberg

Susana M. Cedres

Åslaug Helland

机构：

[1] Oslo University Hospital,Department of Oncology

[2] Oslo University Hospital,Department of Cancer Genetics, Institute for Cancer Research

[3] University of Western Australia,National Centre for Asbestos Related Diseases, Institute for Respiratory Health

[4] Sir Charles Gairdner Hospital,Department of Medical Oncology

[5] Oslo University Hospital,Department of Tumor Biology, Institute for Cancer Research

[6] Ultimovacs,Department of Oncology and Clinical Cancer Research Center

[7] Aalborg University Hospital,Department of Clinical Medicine, Faculty of Medicine

[8] Aalborg University,Thoracic Oncology Center, Theme Cancer

[9] Karolinska University Hospital,Oncology Department

[10] Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology,Faculty of Medicine

[11] University of Oslo,undefined

来源：

Journal of Translational Medicine | / 19卷

关键词：

Malignant pleural mesothelioma; Telomerase vaccine; Immunotherapy; hTERT; Nivolumab; Ipilimumab; Biomarker; Immune response;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY) a randomised, open-label, phase 3 study
Lena, Herve
Greillier, Laurent
Cropet, Claire
Bylicki, Olivier
Monnet, Isabelle
Audigier-Valette, Clarisse
Falchero, Lionel
Vergnenegre, Alain
Demontrond, Pierre
Geier, Margaux
Guisier, Florian
Hominal, Stephane
Locher, Chrystele
Corre, Romain
Chouaid, Christos
Ricordel, Charles
LANCET RESPIRATORY MEDICINE, 2025, 13 (02) : 141 - 152
[32] Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study
Wei, Qing
Xu, Xiaoqing
Li, Jingjing
Wang, Chang
Chen, Weijun
Xie, Yanru
Luo, Cong
Chen, Lei
Chu, Jiadong
Wu, Wei
Han, Zhe
Yang, Yanlian
Hu, Zhiyuan
Xu, Qi
Ying, Jieer
ONCOLOGIST, 2024, 29 (04) : e364 - e578
[33] ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
Wrangle, John M.
Velcheti, Vamsidhar
Patel, Manish R.
Garrett-Mayer, Elizabeth
Hill, Elizabeth G.
Ravenel, James G.
Miller, Jeffrey S.
Farhad, Mohammad
Anderton, Kate
Lindsey, Kathryn
Taffaro-Neskey, Michele
Sherman, Carol
Suriano, Samantha
Swiderska-Syn, Marzena
Sion, Amy
Harris, Joni
Edwards, Andie R.
Rytlewski, Julie A.
Sanders, Catherine M.
Yusko, Erik C.
Robinson, Mark D.
Krieg, Carsten
Redmond, William L.
Egan, Jack O.
Rhode, Peter R.
Jeng, Emily K.
Rock, Amy D.
Wong, Hing C.
Rubinstein, Mark P.
LANCET ONCOLOGY, 2018, 19 (05) : 694 - 704
[34] Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
Shah, Manish A.
Udrea, Anghel Adrian
Bondarenko, Igor
Mansoor, Was
Sanchez, Raquel Guardeno
Sarosiek, Tomasz
Bozzarelli, Silvia
Schenker, Michael
Gomez-Martin, Carlos
Morgan, Carys
oezgueroglu, Mustafa
Pikiel, Joanna
Kalofonos, Haralabos P.
Wojcik, Elzbieta
Buchler, Tomas
Swinson, Daniel
Cicin, Irfan
Joseph, Mano
Vynnychenko, Ihor
Luft, Alexander Valerievich
Enzinger, Peter C.
Salek, Tomas
Papandreou, Christos
Tournigand, Christophe
Maiello, Evaristo
Wei, Ran
Ferry, David
Gao, Ling
Oliveira, Joana M.
Ajani, Jaffer A.
CANCERS, 2022, 14 (05)
[35] Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial
Crabb, Simon
Wickens, Robin
Jane-Bibby, Sarah
Dunkley, Denise
Lawrence, Megan
Knight, Allen
Jones, Robert
Birtle, Alison
Huddart, Robert
Linch, Mark
Martin, Jonathan
Coleman, Adam
Boukas, Konstantinos
Markham, Hannah
Griffiths, Gareth
BMC CANCER, 2023, 23 (01)
[36] Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial
Simon Crabb
Robin Wickens
Sarah Jane-Bibby
Denise Dunkley
Megan Lawrence
Allen Knight
Robert Jones
Alison Birtle
Robert Huddart
Mark Linch
Jonathan Martin
Adam Coleman
Konstantinos Boukas
Hannah Markham
Gareth Griffiths
BMC Cancer, 23
[37] A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
Brown, Nicholas F.
Ng, Stasya M.
Brooks, Claire
Coutts, Tim
Holmes, Jane
Roberts, Corran
Elhussein, Leena
Hoskin, Peter
Maughan, Tim
Blagden, Sarah
Mulholland, Paul
BMC CANCER, 2020, 20 (01)
[38] FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC
Spigel, David R.
Chaft, Jamie E.
Gettinger, Scott
Chao, Bo H.
Dirix, Luc
Schmid, Peter
Chow, Laura Q. M.
Hicks, Rodney J.
Leon, Larry
Fredrickson, Jill
Kowanetz, Marcin
Sandler, Alan
Funke, Roel
Rizvi, Naiyer A.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1733 - 1742
[39] Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
Liu, Yanfei
Song, Yuqin
Zuo, Shubo
Zhang, Xian
Liu, Hui
Wang, Jingwen
Wang, Jingbo
Tang, Yongjing
Zheng, Wen
Ying, Zhitao
Ping, Lingyan
Zhang, Chen
Wu, Meng
Zhu, Jun
Xie, Yan
FRONTIERS IN IMMUNOLOGY, 2023, 14
[40] A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol
Nicholas F. Brown
Stasya M. Ng
Claire Brooks
Tim Coutts
Jane Holmes
Corran Roberts
Leena Elhussein
Peter Hoskin
Tim Maughan
Sarah Blagden
Paul Mulholland
BMC Cancer, 20

← 1 2 3 4 5 →